Evidence question
What does randomized evidence show for semaglutide in adults with overweight or obesity?
Result / effect
In STEP 1, mean change at 68 weeks was −15.3 kg with semaglutide plus lifestyle intervention and −2.6 kg with placebo plus lifestyle intervention.
Evidence chain
Population
Adults with overweight or obesity; results differ across trials that include or exclude type 2 diabetes.
Endpoint
Change in body weight, often expressed in kilograms or percentage of baseline weight.
Evidence level
High. The direction and size of effect are supported by large phase 3 randomized trials. Results from a specific trial should not be generalized to every formulation, population, or treatment duration.
What this record does not establish
- The pivotal trial excluded people with diabetes and combined medication with lifestyle intervention.
- Gastrointestinal adverse events and treatment discontinuation affect real-world use.
- A trial result does not establish an individualized treatment choice.
Linked study records
Sources
- STEP 1 trial, PubMedRandomized controlled trial
- Wegovy prescribing information, DailyMedRegulatory label